| Dr Stephen Charles Moore, MD | |
|
150 Providence Rd, Charlotte, NC 28207-1218 | |
| (704) 973-2106 | |
| (704) 973-2395 |
| Full Name | Dr Stephen Charles Moore |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 34 Years |
| Location | 150 Providence Rd, Charlotte, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275523102 | NPI | - | NPPES |
| 8960218 | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 9400940 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Novant Health Presbyterian Medical Center | Charlotte, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Novant Medical Group Inc | 1153234893 | 1996 |
News Archive
New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.
Diabetes affects more than 23 million people in the United States today and another 54 million people have pre-diabetes, according to the Centers for Disease Control and Prevention. However, while nearly 60 percent of Americans are concerned about developing diabetes, many aren't taking the necessary steps to protect their health, according to a recent study by the International Diabetes Center and Abbott.
The Experimental Cancer Medicine Centres (ECMC) network, which runs UK clinical studies of the newest cancer treatments, has been awarded a second wave of £35M funding for the next five years.
Researchers have discovered a new family of agents that inhibit the growth of estrogen-dependent breast cancer cells. The finding, described at a meeting of the Endocrine Society, has opened an avenue of research into new drugs to combat estrogen-dependent breast cancers.
Cornerstone Pharmaceuticals, Inc., a private pharmaceutical company, with a singular focus on cancer metabolism, has announced today that U.S. regulatory clearance has been obtained for the initiation of a physician-sponsored, Phase I human clinical trial of Cornerstone's first-in-class anticancer agent, CPI-613.
› Verified 4 days ago
| Entity Name | Novant Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366409492 PECOS PAC ID: 1153234893 Enrollment ID: O20031121000692 |
News Archive
New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.
Diabetes affects more than 23 million people in the United States today and another 54 million people have pre-diabetes, according to the Centers for Disease Control and Prevention. However, while nearly 60 percent of Americans are concerned about developing diabetes, many aren't taking the necessary steps to protect their health, according to a recent study by the International Diabetes Center and Abbott.
The Experimental Cancer Medicine Centres (ECMC) network, which runs UK clinical studies of the newest cancer treatments, has been awarded a second wave of £35M funding for the next five years.
Researchers have discovered a new family of agents that inhibit the growth of estrogen-dependent breast cancer cells. The finding, described at a meeting of the Endocrine Society, has opened an avenue of research into new drugs to combat estrogen-dependent breast cancers.
Cornerstone Pharmaceuticals, Inc., a private pharmaceutical company, with a singular focus on cancer metabolism, has announced today that U.S. regulatory clearance has been obtained for the initiation of a physician-sponsored, Phase I human clinical trial of Cornerstone's first-in-class anticancer agent, CPI-613.
› Verified 4 days ago
| Entity Name | Novant Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306950282 PECOS PAC ID: 1153234893 Enrollment ID: O20040204001028 |
News Archive
New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.
Diabetes affects more than 23 million people in the United States today and another 54 million people have pre-diabetes, according to the Centers for Disease Control and Prevention. However, while nearly 60 percent of Americans are concerned about developing diabetes, many aren't taking the necessary steps to protect their health, according to a recent study by the International Diabetes Center and Abbott.
The Experimental Cancer Medicine Centres (ECMC) network, which runs UK clinical studies of the newest cancer treatments, has been awarded a second wave of £35M funding for the next five years.
Researchers have discovered a new family of agents that inhibit the growth of estrogen-dependent breast cancer cells. The finding, described at a meeting of the Endocrine Society, has opened an avenue of research into new drugs to combat estrogen-dependent breast cancers.
Cornerstone Pharmaceuticals, Inc., a private pharmaceutical company, with a singular focus on cancer metabolism, has announced today that U.S. regulatory clearance has been obtained for the initiation of a physician-sponsored, Phase I human clinical trial of Cornerstone's first-in-class anticancer agent, CPI-613.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Stephen Charles Moore, MD Po Box 60447, Charlotte, NC 28260-0447 Ph: (704) 973-2106 | Dr Stephen Charles Moore, MD 150 Providence Rd, Charlotte, NC 28207-1218 Ph: (704) 973-2106 |
News Archive
New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.
Diabetes affects more than 23 million people in the United States today and another 54 million people have pre-diabetes, according to the Centers for Disease Control and Prevention. However, while nearly 60 percent of Americans are concerned about developing diabetes, many aren't taking the necessary steps to protect their health, according to a recent study by the International Diabetes Center and Abbott.
The Experimental Cancer Medicine Centres (ECMC) network, which runs UK clinical studies of the newest cancer treatments, has been awarded a second wave of £35M funding for the next five years.
Researchers have discovered a new family of agents that inhibit the growth of estrogen-dependent breast cancer cells. The finding, described at a meeting of the Endocrine Society, has opened an avenue of research into new drugs to combat estrogen-dependent breast cancers.
Cornerstone Pharmaceuticals, Inc., a private pharmaceutical company, with a singular focus on cancer metabolism, has announced today that U.S. regulatory clearance has been obtained for the initiation of a physician-sponsored, Phase I human clinical trial of Cornerstone's first-in-class anticancer agent, CPI-613.
› Verified 4 days ago
Jackie Alan Lucas, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1025 Morehead Medical Dr, Ste 450, Charlotte, NC 28204 Phone: 704-446-7800 | |
Lynn Amy Boardman, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1350 S Kings Dr, Charlotte, NC 28207 Phone: 704-446-1544 | |
Dr. Simon Vivian Ward Iii, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1918 Randolph Rd, Suite 670, Charlotte, NC 28207 Phone: 704-384-1620 Fax: 704-384-1626 | |
Curtis Lee Flood, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 6331 Carmel Rd Ste 102, Charlotte, NC 28226 Phone: 980-367-4363 Fax: 704-316-2558 | |
Grant Blanchard, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1350 S Kings Dr, Charlotte, NC 28207 Phone: 704-446-1544 | |
Roland Pixley, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1025 Morehead Medical Dr, Ste 400, Charlotte, NC 28204 Phone: 704-446-1700 | |
Katherine Elizabeth Akeley, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1350 S Kings Dr, Charlotte, NC 28207 Phone: 704-446-1544 |